GSE137912 Single cell RNA sequencing of cells treated with a KRAS G12C specific inhibitor

This study uncovers a flexible non-uniform fitness mechanism that enables groups of cells within a population to rapidly bypass the effect of treatment. This adaptive process must be overcome if we are to achieve complete and durable responses in the clinic.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research

Related Links:

Conclusions: Niche mutations exhibited an increased risk of death when compared with EGFR mutations and a similar risk of death when compared with KRAS mutations. PMID: 32082488 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
CONCLUSIONS: We strictly determined prognostic genes of NSCLC, which would contribute to its carcinogenesis investigation and therapeutic methods improvement. PMID: 32083573 [PubMed - as supplied by publisher]
Source: Cancer Biomarkers - Category: Cancer & Oncology Tags: Cancer Biomark Source Type: research
CONCLUSIONS: We established a prognostic model for lung adenocarcinoma, and further concluded that SMARCA4, GNAS and TSC2 were a gene signature which plays a prognostic role. PMID: 32083571 [PubMed - as supplied by publisher]
Source: Cancer Biomarkers - Category: Cancer & Oncology Tags: Cancer Biomark Source Type: research
Lung adenocarcinoma (LUAD) is a common histological type of non-small cell lung cancer (NSCLC), accounting for nearly 40% of all lung cancers [1]. Current research has identified several LUAD-specific oncoproteins with differential expression of wildtype or mutant forms, which includes the REarranged during Transfection (RET) receptor tyrosine kinase (RTK). The expression and activation of RET has been implicated in multiple cancers, including lung [2,3]. RET is expressed at low levels in normal lung tissues, however RET gene rearrangements give rise to chimeric proteins with constitutive kinase activity that drive tumouri...
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
AbstractAnti ‐programmed cell death 1 (PD‐1) and its ligand (PD‐L1) has emerged as a novel immunotherapy for non‐small cell lung cancer (NSCLC). However, the proportion of patients who may benefit from immunotherapy is limited and the factors sensitive or resistant to immunotherapy are not completely cle ar. Therefore, to identify reliable biomarkers as predictors of clinical response and resistance to anti‐PD‐1/PD‐L1 therapies have become increasingly important. Here, we report a case of a patient with bone metastatic NSCLC, who achieved a pathologic complete response after preoperative pembr olizumab treatm...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: CASE REPORT Source Type: research
Despite the increase of therapeutic options available in clinical setting, non-small cell lung cancer (NSCLC) still remains the leading cause of cancer-related death in both sexes worldwide, representing over 85% of all lung cancers.[1] The clinical knowledge of the epidermal growth factor receptor (EGFR) molecular status, emerging over a decade ago, has led to a dramatic shift in the treatment paradigm of metastatic NSCLC. The prevalence of EGFR mutations ranges from 10% to 15% in Caucasian patients [2] and up to 50% in East-Asian patients, [3] mainly but not only with adenocarcinoma histology, female gender and quite pec...
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Source Type: research
Conclusion: The miR-1323 promoted LUAD migration through inhibiting Cbl-b expression. High miR-1323 expression predicted poor prognosis in LUAD patients.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: Cancer diagnosis should always be considered in patients with unprovoked thrombosis and, if NSCLC is diagnosed, genetic alterations should be always sought after. A possible relation between venous thromboembolism and oncogenic drivers, particularly for ALK translocations, has been hypothesized. Similarly to ALK-positive NSCLC, ROS1 rearranged disease has been associated with an increased thromboembolic risk. Further studies are needed to better evaluate this relation and to evaluate the potential benefit of a prophylactic anticoagulating treatment in this subset of patients. PMID: 32066344 [PubMed - as supplied by publisher]
Source: Tumori - Category: Cancer & Oncology Tags: Tumori Source Type: research
Abstract The purpose of the present study was to evaluate the clinical profiles and treatment outcomes of patients with lung cancer admitted to the Medical Psychiatric Unit (MPU), which is built for patients with physical and severe psychiatric disorders. All medical records of patients with lung cancer admitted to the MPU of Tachikawa hospital were reviewed. The clinical outcomes of these patients were retrospectively evaluated between January 2010 and December 2016. A total of 24 patients in the MPU were histologically or cytologically diagnosed with primary lung cancer. Of these, 20 patients had schizophrenia, ...
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: Mol Clin Oncol Source Type: research
Advanced non-small cell lung cancer (NSCLC) is a devastating disease that is incurable and associated with poor outcomes worldwide [1]. Targeted therapies with predictive biomarkers have changed the health care strategy for metastatic NSCLC patients [2]. An anaplastic lymphoma kinase (ALK) gene rearrangement is a distinct driving mutation that occurs in as many as 8% of patients with NSCLC. Of note, different fusion partners can influence the response to ALK inhibition in patients with NSCLC [3].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Clinical Trials | Genetics | Jordan Health | Lung Cancer | Middle East Health | Study